Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Public Storage (PSA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Public Storage — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.75 (market cap $4.49B), while Public Storage trades at $322.35 (market cap $57.71B). The key difference: Public Storage is far larger — about 12.9× ACADIA Pharmaceuticals Inc.'s market cap, and Public Storage pays a 3.65% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | PSA | |
|---|---|---|
Market Cap | $4.49B | $57.71B |
Sector | Health | Real Estate |
52-Week High | $28.06 | $329.64 |
52-Week Low | $20.06 | $258.44 |
Enterprise Value | $3.69B | $71.96B |
Dividend Yield | — | 3.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Public Storage (PSA) trades at $328.69, near analyst consensus targets, with a slight 0.29% dip. The stock shows strong technical momentum with bullish moving averages and support at $321. Fundamentally, PSA maintains robust profitability with a 39.16% net margin and consistent earnings beats, though valuation multiples like P/E of 33.47 appear elevated. Recent developments include a $1.2B Canadian acquisition and enhanced liquidity facilities, signaling growth initiatives.
Outlook remains positive driven by operational strength and strategic expansions, but risks include high valuation sensitivity and interest rate exposure. Analyst consensus leans Hold (62.86%), with a $330.38 price target suggesting limited near-term upside. Investors should weigh solid fundamentals against premium pricing in a normalized REIT environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Public Storage
Public Storage is the largest owner of self-storage facilities in the U.S. with more than 2,800 self-storage facilities in 39 states and approximately 200 million square feet of rentable space. Through equity interests, it also has exposure to the European self-storage market through Shurgard Self Storage and to an additional 28 million net rentable square feet of industrial space in the United States through PS Business Parks.
Read more on PSA →
